Market Research Logo

Benign Prostatic Hyperplasia - Pipeline Review, H2 2015

Benign Prostatic Hyperplasia - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Benign Prostatic Hyperplasia - Pipeline Review, H2 2015’, provides an overview of the Benign Prostatic Hyperplasia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Benign Prostatic Hyperplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Benign Prostatic Hyperplasia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Benign Prostatic Hyperplasia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Benign Prostatic Hyperplasia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Benign Prostatic Hyperplasia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Benign Prostatic Hyperplasia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Benign Prostatic Hyperplasia Overview
Therapeutics Development
Pipeline Products for Benign Prostatic Hyperplasia - Overview
Pipeline Products for Benign Prostatic Hyperplasia - Comparative Analysis
Benign Prostatic Hyperplasia - Therapeutics under Development by Companies
Benign Prostatic Hyperplasia - Therapeutics under Investigation by Universities/Institutes
Benign Prostatic Hyperplasia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Benign Prostatic Hyperplasia - Products under Development by Companies
Benign Prostatic Hyperplasia - Products under Investigation by Universities/Institutes
Benign Prostatic Hyperplasia - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
AmVac AG
AndroScience Corporation
Aphios Corporation
Ausio Pharmaceuticals, LLC
BCWorld Pharm Co. Ltd.
Biolab Sanus Farmaceutica Ltda.
Chong Kun Dang Pharmaceutical Corp.
Dongkook Pharmaceutical Co., Ltd.
Euroscreen S.A.
Hanmi Pharmaceuticals, Co. Ltd.
IntelGenx Corp.
Jeil Pharmaceutical Co., Ltd.
KAEL-GemVax Co., Ltd.
Kaken Pharmaceutical Co., Ltd.
Meiji Seika Pharma Co., Ltd.
Mezzion Pharma Co. Ltd.
Monosol Rx, LLC
Nymox Pharmaceutical Corporation
Ono Pharmaceutical Co., Ltd.
Quest PharmaTech Inc.
SK Chemicals Co., Ltd.
SOM Innovation Biotech SL
Sophiris Bio, Inc.
Yungjin Pharm. Co., Ltd.
Benign Prostatic Hyperplasia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(dutasteride + tadalafil) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(solifenacin succinate + tamsulosin hydrochloride) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(tamsulosin hydrochloride + dutasteride) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ADX-68692 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMV-110 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASC-JM.X2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AUS-131 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BCWPE-004 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BL-214 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CKD-902 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ESN-364 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fexapotide triflutate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HCP-1303 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HIP-1402 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
INT-0031 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
L-1AD3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MCS-2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Micselon - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NCE-403 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ONO-8430506 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-40542 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SL-052 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SOM-2391 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SOM-2393 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sperol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tadalafil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
talaporfin sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tamsulosin hydrochloride CR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tamsulosin hydrochloride DR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tertomotide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
topsalysin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
udenafil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
YBH-1603 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
YOB-1604 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Benign Prostatic Hyperplasia - Recent Pipeline Updates
Benign Prostatic Hyperplasia - Dormant Projects
Benign Prostatic Hyperplasia - Discontinued Products
Benign Prostatic Hyperplasia - Product Development Milestones
Featured News & Press Releases
Apr 01, 2015: Nymox Announces Phase 3 BPH Studies
Dec 15, 2014: Sophiris Bio Reports Administrative Interim Analysis for the PLUS-
Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia
Nov 02, 2014: Nymox NX-1207 BPH Pivotal Phase 3 U.S. Studies NX02-0017 and NX02-0018 Fail to Meet Primary Efficacy Endpoints
Sep 02, 2014: Sophiris Bio Reports Completion of Enrollment in the PLUS-
Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia
Jul 22, 2014: Nymox Announces Positive Efficacy Results in Phase 3 Repeat Injection Trial of NX-1207 for BPH
Jul 15, 2014: Nymox Announces Completion of Enrollment for Second BPH Re-Injection Study
Jun 17, 2014: Nymox Reports Positive Update on Nerve Sparing and Sexual Function Preservation in Men Treated With NX-1207
Jun 11, 2014: Nymox Reports Positive New Safety Study Data for Phase 3 BPH Drug
May 08, 2014: Nymox Announces Completion of Second Pivotal Phase 3 NX-1207 Trial for BPH
Nov 11, 2013: Nymox Reports Update and Positive Safety Data for Phase 3 NX02-0022 Reinjection Study of NX-1207 for BPH
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Benign Prostatic Hyperplasia, H2 2015
Number of Products under Development for Benign Prostatic Hyperplasia - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd...1)
Products under Investigation by Universities/Institutes, H2 2015
Benign Prostatic Hyperplasia - Pipeline by Addex Therapeutics Ltd, H2 2015
Benign Prostatic Hyperplasia - Pipeline by AmVac AG, H2 2015
Benign Prostatic Hyperplasia - Pipeline by AndroScience Corporation, H2 2015
Benign Prostatic Hyperplasia - Pipeline by Aphios Corporation, H2 2015
Benign Prostatic Hyperplasia - Pipeline by Ausio Pharmaceuticals, LLC, H2 2015
Benign Prostatic Hyperplasia - Pipeline by BCWorld Pharm Co. Ltd., H2 2015
Benign Prostatic Hyperplasia - Pipeline by Biolab Sanus Farmaceutica Ltda., H2 2015
Benign Prostatic Hyperplasia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015
Benign Prostatic Hyperplasia - Pipeline by Dongkook Pharmaceutical Co., Ltd., H2 2015
Benign Prostatic Hyperplasia - Pipeline by Euroscreen S.A., H2 2015
Benign Prostatic Hyperplasia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2015
Benign Prostatic Hyperplasia - Pipeline by IntelGenx Corp., H2 2015
Benign Prostatic Hyperplasia - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2015
Benign Prostatic Hyperplasia - Pipeline by KAEL-GemVax Co., Ltd., H2 2015
Benign Prostatic Hyperplasia - Pipeline by Kaken Pharmaceutical Co., Ltd., H2 2015
Benign Prostatic Hyperplasia - Pipeline by Meiji Seika Pharma Co., Ltd., H2 2015
Benign Prostatic Hyperplasia - Pipeline by Mezzion Pharma Co. Ltd., H2 2015
Benign Prostatic Hyperplasia - Pipeline by Monosol Rx, LLC, H2 2015
Benign Prostatic Hyperplasia - Pipeline by Nymox Pharmaceutical Corporation, H2 2015
Benign Prostatic Hyperplasia - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015
Benign Prostatic Hyperplasia - Pipeline by Quest PharmaTech Inc., H2 2015
Benign Prostatic Hyperplasia - Pipeline by SK Chemicals Co., Ltd., H2 2015
Benign Prostatic Hyperplasia - Pipeline by SOM Innovation Biotech SL, H2 2015
Benign Prostatic Hyperplasia - Pipeline by Sophiris Bio, Inc., H2 2015
Benign Prostatic Hyperplasia - Pipeline by Yungjin Pharm. Co., Ltd., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Benign Prostatic Hyperplasia Therapeutics - Recent Pipeline Updates, H2 2015
Benign Prostatic Hyperplasia - Dormant Projects, H2 2015
Benign Prostatic Hyperplasia - Dormant Projects (Contd...1), H2 2015
Benign Prostatic Hyperplasia - Dormant Projects (Contd...2), H2 2015
Benign Prostatic Hyperplasia - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Benign Prostatic Hyperplasia, H2 2015
Number of Products under Development for Benign Prostatic Hyperplasia - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report